2025 · 3rd Quarter (July 1 - Sep 30)
Filed by BRISTOL-MYERS SQUIBB COMPANY.
Open official filingSource-reported fields
Expense method: A
Literal source text
H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act Discussions regarding H.R.1, One Big Beautiful Bill Act regarding bio-pharmaceutical provisions Biosimilars reimbursement issues H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025 H.R.1968, lobbied for passage of the Continuing Resolution to include PBM reform
Literal federal measure citations: H.R.1492, H.R.1, H.R.4299, H.R.1968
Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act Issues related to the six protected classes of medicines under Medicare Part D, regarding all bio-pharmaceutical issues
Literal federal measure citations: H.R.7635
Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation
Intellectual Property Reform concerning bio-pharmaceutical industry
S.864, HELP Copays Act S.526, Pharmacy Benefit Manager Transparency Act of 2025 H.R.3285, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act Modernizing and Ensuring Equity Act H.R.3521, Clinical Trials Modernization Act Discussions regarding Continuing Resolution to include PBM reform, H.R.1968
Literal federal measure citations: S.864, S.526, H.R.3285, S.1339, H.R.3521, H.R.1968
International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.
